New targeted medicine for advanced triple-negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This study tests a new drug (9MW2821) against standard chemotherapy for people with triple-negative breast cancer that has spread or come back after prior treatments. The new drug is designed to target and destroy cancer cells more precisely, potentially offering better outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have triple-negative breast cancer that has spread or come back, and you've already had certain treatments (chemotherapy, immunotherapy, or targeted therapy).
- You are between 18 and 75 years old and your health is fairly good (able to do light activities).
- You have at least one tumor that can be measured on a scan, and you can provide a tissue sample from your tumor.
- You don't have serious health issues like lung disease, heart disease, severe nerve pain, or uncontrolled diabetes.
- You agree to use birth control during the study and for at least 6 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, 9MW2821 (sometimes with a PD-1 inhibitor), for people with advanced triple-negative breast cancer. It may be an option if you've already tried standard treatments or haven't started any yet.
This Phase 2 trial tests a treatment plan for triple-negative breast cancer that has come back or kept progressing after prior immunotherapy (sometimes along with targeted therapy or chemotherapy). It may help by trying to make the cancer more controllable when it has become resistant to earlier treatment.
This Phase 2 trial tests a treatment for people with triple-negative breast cancer that has come back or spread and has continued to progress despite earlier therapies. It may help by trying a new approach in patients who still have enough health to safely receive more treatment.
This study tests a new way to choose treatment for advanced triple-negative breast cancer, based on a special analysis of your tumor. The goal is to find a treatment that works better for your specific cancer type.
This study tests a new drug combination (called 9MW2821 with other cancer drugs) for women with advanced gynecological cancers that have not responded to other treatments. The goal is to see if the combination is safe and effective in shrinking tumors.
This trial tests a new drug called LM-108 combined with a PD-1 inhibitor (a type of immunotherapy) for people with triple-negative breast cancer that has come back or spread. It aims to see if this combination can help shrink tumors or slow the disease.
Hear when a new Locally Advanced or Metastatic Triple-negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.